Eli Lilly News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

25.04.17	Eli Lilly And Co. Announces 18% Increase In Q1 Profit (RTTNews)
25.04.17	Lilly Reports First-Quarter 2017 Results (PR Newswire)
24.04.17	Lilly :Phase 3 MONARCH 3 Breast Cancer Study Of Abemaciclib Shows Superior PFS (RTTNews)
24.04.17	Lilly Announces Phase 3 MONARCH 3 Breast Cancer Study of Abemaciclib Demonstrated Superior Progression-Free Survival at Interim Analysis (PR Newswire)
24.04.17	Drug Makers Stocks Under Scanner -- Bristol-Myers, AstraZeneca, Eli Lilly, and Immune Pharma (PR Newswire)
20.04.17	Lilly to Present Data for Galcanezumab for the Prevention of Migraine at the American Academy of Neurology (AAN) Annual Meeting (PR Newswire)
19.04.17	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Eli Lilly and Company - LLY (PR Newswire)
17.04.17	MÄRKTE USA/Berichtssaison verdrängt geopolitische -2- (Dow Jones)
17.04.17	MÄRKTE USA/Berichtssaison verdrängt geopolitische Sorgen an der Wall Street (Dow Jones)
17.04.17	MÄRKTE USA/Berichtssaison verdrängt geopolitische Sorgen an der Wall Street (Dow Jones)
17.04.17	FDA Says No To INCY, ZTS Snaps Up NVET, MDXG On The Move (RTTNews)
14.04.17	Eli Lilly And Incyte Say FDA Issues CRL For Baricitinib (RTTNews)
14.04.17	U.S. FDA Issues Complete Response Letter for Baricitinib (PR Newswire)
11.04.17	Lilly Confirms Date and Conference Call for First-Quarter 2017 Financial Results Announcement (PR Newswire)
07.04.17	Life with Type 1 Diabetes Made a Little Easier through Lilly Diabetes Scholarship Donations for Camps, College and Conferences (PR Newswire)
04.04.17	Lilly and Ohio University Heritage College of Osteopathic Medicine Partner on Rotation Program for Medical Students (PR Newswire)
24.03.17	Eli Lilly Plans $850 Mln Investments In U.S. Operations In FY17 - Quick Facts (RTTNews)
24.03.17	Lilly Announces $850 Million Investment in U.S. Capital Projects in 2017 (PR Newswire)
24.03.17	Biotech Stocks Facing FDA Decision In April (RTTNews)
23.03.17	Lilly and the William Sansum Diabetes Center announce a five-year research collaboration (PR Newswire)
20.03.17	Lilly: Phase 3 MONARCH 2 Breast Cancer Study Of Abemaciclib Met Primary Endpoint (RTTNews)
20.03.17	Lilly Announces Phase 3 MONARCH 2 Breast Cancer Study of Abemaciclib Met Primary Endpoint of Progression-Free Survival (PR Newswire)
17.03.17	First dedicated outcome trials of empagliflozin in chronic heart failure initiated (PR Newswire)
17.03.17	Technical Reports on Drug Makers Stocks -- Bristol-Myers Squibb, AstraZeneca, Eli Lilly, and Immune Pharma (PR Newswire)
13.03.17	OilPrice.com: The Next Big Biotech Breakthrough Could Just be on the Horizon (PR Newswire)
07.03.17	MÄRKTE USA/Konsolidierung geht weiter - Trump belastet Pharmawerte (Dow Jones)
05.03.17	Lilly: Taltz Shows Superior Efficacy Compared To Stelara In Plaque Psoriasis (RTTNews)
04.03.17	New Head-to-Head Data Shows Significantly Higher Response Rates for Lilly's Taltz® (ixekizumab) Compared to Stelara® (ustekinumab) in Patients with Moderate-to-Severe Plaque Psoriasis (PR Newswire)
03.03.17	Lilly Diabetes Becomes 'Official Diabetes Health Partner of NASCAR®' (PR Newswire)
02.03.17	Lilly Announces Changes in Senior Management (PR Newswire)
01.03.17	Lilly Completes Acquisition of CoLucid Pharmaceuticals (PR Newswire)
28.02.17	Lilly to Present New Data for Taltz® (ixekizumab) in Psoriasis and Psoriatic Arthritis at the American Academy of Dermatology (AAD) Annual Meeting (PR Newswire)
15.02.17	Additional results from pivotal RA-BEAM study published in New England Journal of Medicine show baricitinib-treated patients demonstrated sustained improvement in rheumatoid arthritis compared to... (PR Newswire)
13.02.17	European Commission Approves Once-Daily Olumiant Tablets for Treatment of Adults with Moderate-to-Severe Active Rheumatoid Arthritis (PR Newswire)
13.02.17	European Commission Approves Once-Daily Olumiant Tablets for Treatment of Adults with Moderate-to-Severe Active Rheumatoid Arthritis (PR Newswire)
09.02.17	Lilly To Present At Leerink Partners Global Healthcare Conference (PR Newswire)
09.02.17	Carolyn R. Bertozzi, Ph.D., Elected to Lilly Board of Directors (PR Newswire)
08.02.17	Lilly to Present at Cowen Health Care Conference (PR Newswire)
08.02.17	Lilly's Trulicity Label Updated On Basal Insulin (RTTNews)
08.02.17	Lilly's Trulicity® (dulaglutide) Label Updated to Include Use in Combination with Basal Insulin for Adults with Type 2 Diabetes (PR Newswire)
07.02.17	New Research Reveals Powerful Health Benefits of Dog Companionship (PR Newswire)
07.02.17	Technical Reports on Drug Makers Stocks -- Bristol-Myers Squibb, AstraZeneca, Eli Lilly, and Immune Pharma (PR Newswire)
02.02.17	Japan IP High Court Rules In Lilly's Favor On Alimta Vitamin Regimen Patents (PR Newswire)
01.02.17	Experten: Pharmakonzerne kommen bei Treffen mit Trump glimpflich davon (AWP)
31.01.17	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Into Whether the Sale of CoLucid Pharmaceuticals, Inc. to Eli Lilly & Co. for $46.50 Per Share is Fair to Shareholders -- CLCD (PR Newswire)
31.01.17	Trump Calls For Increased Competition To Reduce Drug Prices (RTTNews)
31.01.17	Analysten erwarten für Roche Jahresumsatz von 50,8 Milliarden Franken (AWP)
31.01.17	Eli Lilly legt dank neuer Medikamente zu (AWP)
31.01.17	Eli Lilly Q4 Profit Misses, But Revenues Beat (RTTNews)
31.01.17	Eli Lilly And Co. Announces 22% Gain In Q4 Profit (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

20.12.24		Freundlicher Handel in New York: Dow Jones beendet die Sitzung weit in der Gewinnzone
20.12.24		Handel in New York: Am Freitagnachmittag Gewinne im Dow Jones
20.12.24		Dow Jones aktuell: Dow Jones notiert am Mittag im Plus
20.12.24		Verluste in Europa: Euro STOXX 50 letztendlich leichter
20.12.24		Schwacher Handel: SMI schliesst mit Verlusten
20.12.24		Schwache Performance in New York: S&P 500 notiert zum Handelsstart im Minus
20.12.24		Handel in Zürich: SMI verbucht Verluste
20.12.24		Börse Frankfurt: So steht der LUS-DAX am Nachmittag

20.12.24

Freundlicher Handel in New York: Dow Jones beendet die Sitzung weit in der Gewinnzone

20.12.24

Handel in New York: Am Freitagnachmittag Gewinne im Dow Jones

20.12.24

Dow Jones aktuell: Dow Jones notiert am Mittag im Plus

20.12.24

Verluste in Europa: Euro STOXX 50 letztendlich leichter

20.12.24

Schwacher Handel: SMI schliesst mit Verlusten

20.12.24

Schwache Performance in New York: S&P 500 notiert zum Handelsstart im Minus